• HOME
  • ABOUT US
  • PRODUCTS
    • LIST OF COPP
    • LIST OF PRODUCTS
  • CAREER
  • BLOG
  • CONTACT US
  • HOME
  • ABOUT US
  • PRODUCTS
    • LIST OF COPP
    • LIST OF PRODUCTS
  • CAREER
  • BLOG
  • CONTACT US

EMA extends Durvalumab’s Therapeutic Indications

October 17, 2020
-
News
-
Posted by seoaccount medivisual
durvalumab's-therapeutic-admaconcology

The European Medicines Agency (EMA’s) Committee for Medicinal Products for Human Use (CHMP) suggested an alteration to the terms of the marketing authorization for the medicinal product durvalumab on 23 July 2020.

An extension to the existing therapeutic indication was adopted by CHMP as follows:

As monotherapy, durvalumab is indicated for managing locally advanced, unresectable non-small cell lung cancer (NSCLC) in individuals whose tumors express PD-L1 on ≥1% of tumor cells and whose disease has not advanced after platinum-based chemoradiation therapy.

In combination with etoposide drug and either cisplatin or carboplatin drug, durvalumab is advocated as the first-line management of individuals having extensive-stage SCLC.

In the updated summary of product characteristics, the detailed recommendations for using this product will be elucidated. After European Commission grants a decision on this modification to the marketing authorization, it will be instantly issued in the revised European public assessment report. This will be then officially available in all the European Union languages.

The summaries of positive opinions will normally be published 67 days from the adoption of the viewpoint and are issued without prejudice to the European Commission decision.

Source

ESMO

Link:

https://www.esmo.org/oncology-news/ema-recommends-extension-of-indications-for-durvalumab [Last accessed on: 16 October, 2020]

Original title of the article

EMA RECOMMENDS EXTENSION OF INDICATIONS FOR DURVALUMAB
← PREVIOUS POST
Novel Guidelines for Treating Advanced Prostate Cancer
NEXT POST →
Anastrozole: An effective drug to treat Breast Cancer

Related News

Other posts that you should not miss.
Infigratinib-for-Cholangiocarcinoma-and-FGFR2-fusions-admac

Study evaluates Infigratinib for Cholangiocarcinoma and FGFR2 fusions

July 28, 2020
-
News

At ESMO (European Society for Medical Oncology) World Congress on Gastrointestinal Cancer 2020 Virtual, it was reported that in patients with CCA (cholangiocarcinoma) and FGFR2 (fibroblast growth factor …

Read More →
Posted by seoaccount medivisual
2 MIN READ
coffee-for-liver-cancer-admac

Coffee: A Brewed Drink to Reduce the risk of Liver Cancer

November 7, 2020
-
News

Coffee drinkers have a special place for coffee. They cannot imagine a day without this drink. It is one of the most popular brewed drinks around the world. …

Read More →
Posted by seoaccount medivisual
5 MIN READ
heart-problem-admac

Heart problems arising due to Cancer Treatment

January 4, 2021
-
News

Cancer treatments- Radiation therapy and chemotherapy are raising the number of people who survive cancer. Though, they can also cause various health issues, including cardiovascular disease. The heart …

Read More →
Posted by seoaccount medivisual
5 MIN READ
Please speak to us:
  • Phone:+91 172 2565161 , +91 172 2565162
  • Email : admac@admacinternational.com
Admac House
SCO 84, Sector 5,
Panchkula (Haryana)
134112 INDIA.
Our aim

At Admac we aim at providing innovative World-Standard medicines for all, at affordable prices. Admac is fully committed towards WHO standards; quality & growth, latest technology & R & D with sheer hard work and dedicated team work.

All Rights Reserved. 2016
Powered  by: Admac Oncology
EMA extends Durvalumab's Therapeutic Indications | Admaconcology